124 related articles for article (PubMed ID: 15493361)
1. Case report and brief review: IL-2-induced myocarditis.
Eisner RM; Husain A; Clark JI
Cancer Invest; 2004; 22(3):401-4. PubMed ID: 15493361
[TBL] [Abstract][Full Text] [Related]
2. Severe myocarditis following high-dose interleukin-2 administration.
Samlowski WE; Ward JH; Craven CM; Freedman RA
Arch Pathol Lab Med; 1989 Aug; 113(8):838-41. PubMed ID: 2787976
[TBL] [Abstract][Full Text] [Related]
3. Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer.
Kragel AH; Travis WD; Steis RG; Rosenberg SA; Roberts WC
Cancer; 1990 Oct; 66(7):1513-6. PubMed ID: 2208002
[TBL] [Abstract][Full Text] [Related]
4. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
Acquavella N; Kluger H; Rhee J; Farber L; Tara H; Ariyan S; Narayan D; Kelly W; Sznol M
J Immunother; 2008; 31(6):569-76. PubMed ID: 18528297
[TBL] [Abstract][Full Text] [Related]
5. High-dose interleukin-2 in metastatic disease: renal cell carcinoma and melanoma.
Dutcher J
Oncology (Williston Park); 2002 Nov; 16(11 Suppl 13):3. PubMed ID: 12469933
[No Abstract] [Full Text] [Related]
6. Fulminant myocarditis owing to high-dose interleukin-2 therapy for metastatic melanoma.
Thavendiranathan P; Verhaert D; Kendra KL; Raman SV
Br J Radiol; 2011 May; 84(1001):e99-e102. PubMed ID: 21511746
[TBL] [Abstract][Full Text] [Related]
7. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma.
White RL; Schwartzentruber DJ; Guleria A; MacFarlane MP; White DE; Tucker E; Rosenberg SA
Cancer; 1994 Dec; 74(12):3212-22. PubMed ID: 7982185
[TBL] [Abstract][Full Text] [Related]
8. Sustained ventricular tachycardia and its successful prophylaxis during high-dose bolus interleukin-2 therapy for metastatic renal cell carcinoma.
Oleksowicz L; Escott P; Leichman GC; Spangenthal E
Am J Clin Oncol; 2000 Feb; 23(1):34-6. PubMed ID: 10683072
[TBL] [Abstract][Full Text] [Related]
9. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma.
Dutcher JP
Oncology (Williston Park); 2002 Nov; 16(11 Suppl 13):4-10. PubMed ID: 12469934
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma.
Hughes T; Klairmont M; Broucek J; Iodice G; Basu S; Kaufman HL
Cancer Immunol Immunother; 2015 Apr; 64(4):459-65. PubMed ID: 25603775
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of the Evolution of Immune Checkpoint Inhibitor Myocarditis With Cardiovascular Magnetic Resonance.
Sato T; Nakamori S; Watanabe S; Nishikawa K; Inoue T; Imanaka-Yoshida K; Ishida M; Sakuma H; Ito M; Dohi K
Circ Cardiovasc Imaging; 2020 Nov; 13(11):e010633. PubMed ID: 33153280
[No Abstract] [Full Text] [Related]
12. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2.
Yang JC; Topalian SL; Schwartzentruber DJ; Parkinson DR; Marincola FM; Weber JS; Seipp CA; White DE; Rosenberg SA
Cancer; 1995 Aug; 76(4):687-94. PubMed ID: 8625167
[TBL] [Abstract][Full Text] [Related]
13. The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma.
MacFarlane MP; Yang JC; Guleria AS; White RL; Seipp CA; Einhorn JH; White DE; Rosenberg SA
Cancer; 1995 Feb; 75(4):1030-7. PubMed ID: 7842405
[TBL] [Abstract][Full Text] [Related]
14. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
[TBL] [Abstract][Full Text] [Related]
15. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.
Du Bois JS; Trehu EG; Mier JW; Shapiro L; Epstein M; Klempner M; Dinarello C; Kappler K; Ronayne L; Rand W; Atkins MB
J Clin Oncol; 1997 Mar; 15(3):1052-62. PubMed ID: 9060545
[TBL] [Abstract][Full Text] [Related]
16. Cardiac magnetic resonance appearance of myocarditis caused by high dose IL-2: similarities to community-acquired myocarditis.
Ingkanisorn WP; Paterson DI; Calvo KR; Rosing DR; Schwartzentruber DJ; Fuisz AR; Arai AE
J Cardiovasc Magn Reson; 2006; 8(2):353-60. PubMed ID: 16669178
[TBL] [Abstract][Full Text] [Related]
17. Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients.
Gitlitz BJ; Hoffman DM; Moldawer N; Belldegrun A; Figlin RA
Cancer J; 2001; 7(2):112-20. PubMed ID: 11324764
[TBL] [Abstract][Full Text] [Related]
18. Guidelines for the safe administration of high-dose interleukin-2.
Schwartzentruber DJ
J Immunother; 2001; 24(4):287-93. PubMed ID: 11565830
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of low-dose intravenous OKT3 and subcutaneous interleukin-2 in metastatic cancer.
Buter J; Janssen RA; Martens A; Sleijfer DT; de Leij L; Mulder NH
Eur J Cancer; 1993; 29A(15):2108-13. PubMed ID: 8297649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
